免疫抑制剤の世界市場2019-2026:機会分析・産業予測

Allied Market Researchが発行した調査報告書(AMR20MY0128)
◆英語タイトル:Immunosuppressants Market by Drug class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, and Others), Indication (Organ Transplantation, Autoimmune Disorders, and Non-Autoimmune Inflammatory Diseases), and Distribution channel (Hospital pharmacies, Retail pharmacies and Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2019–2026
◆商品コード:AMR20MY0128
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2020年1月
◆ページ数:165
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:生命科学
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥558,480見積依頼/購入/質問フォーム
Five UserUSD6,450 ⇒換算¥670,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥935,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、免疫抑制剤の世界市場について調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、疾患別(臓器移植、自己免疫疾患、非自己免疫性炎症性疾患)分析、薬物クラス別(コルチコステロイド、モノクローナル抗体(mAbs)、カルシニューリン阻害剤、mTOR阻害剤、抗増殖剤、その他)分析、流通経路別(病院薬局、小売薬局、オンライン薬局)分析、地域別分析、企業概要などを含め、今後の方向性を明らかに致します。
・イントロダクション
・エグゼクティブサマリ-
・市場概要
・免疫抑制剤の世界市場:疾患別(臓器移植、自己免疫疾患、非自己免疫性炎症性疾患)
・免疫抑制剤の世界市場:薬物クラス別(コルチコステロイド、モノクローナル抗体(mAbs)、カルシニューリン阻害剤、mTOR阻害剤、抗増殖剤、その他)
・免疫抑制剤の世界市場:流通経路別(病院薬局、小売薬局、オンライン薬局)
・免疫抑制剤の世界市場:地域別
・企業概要
【レポートの概要】

The global immunosuppressants market was valued at $13,890.0 million in 2018 and is expected to reach $42,511.37 million by 2026, registering a CAGR of 14.7% from 2019 to 2026. Immunosuppressants suppress the immune response or agents after organ transplantation or grafting procedures. After an organ transplantation, recipient’s body produces certain immune response against it as it considers the organ as an antigen that may harm the body. These immunosuppressants help in combating hyper immune response produced by body’s immune cells. These drugs are a crucial part of organ transplantation procedure as it prevents the body from serious damages.

Increase in incidence of autoimmune disorders such as arthritis, multiple sclerosis, and alopecia areata is the major factor that drives the market growth. In addition, surge in organ transplant procedures such as kidney transplant and liver transplant due to rise in incidence of organ failure further propels the market growth. For instance, as per the U.S. Government Information on Organ Donation and Transplantation, 36,528 organ transplants were performed in 2018 in the country. However, dearth of availability of organ donors and high cost of transplantation as well as immunosuppressant drugs are the limitations for the growth of this market. In addition, side effects of these drugs are expected to hamper the market growth. One of the major side effects of these drugs, especially, corticosteroids is osteoporosis. It is the condition in which density of bones is decreased, increasing the risk of fractures. Any bone in the body can be affected; however, fractures are most commonly seen in the hip, spine, or wrist. On the contrary, increase in use of tissue engineering for generation of implants provides growth opportunities for this market. In addition, rise in disposable income in developing economies, surge in awareness among individuals towards organ donation is anticipated to create lucrative opportunities in the near future.

The market is segmented on the basis of drug class, indication, distribution channel, and region. By drug class, it is divided into corticosteroids, monoclonal antibodies, calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. On the basis of indication, it is categorized into organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
 The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
 It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
 Comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
 Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS
By Drug Class
• Corticosteroids
• Monoclonal Antibodies (mAbs)
• Calcineurin Inhibitors
• mTOR Inhibitors
• Anti-Proliferative Agents
• Others

By Indication
• Organ Transplantation
• Autoimmune Disorders
• Non-Autoimmune Inflammatory Diseases

By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

KEY PLAYERS
• Astellas Pharma, Inc.
• Bristol Myers Squibb
• AbbVie Inc.
• GlaxoSmithKline Plc.
• Intas Pharmaceuticals Ltd.
• Johnson & Johnson
• Mylan Laboratories Inc
• Novartis AG
• Pfizer Inc.
• Sanofi S.A

【レポートの目次】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets

3.3. Porter’S Five Forces Analysis

3.3.1. Moderate Bargaining Power of Buyers
3.3.2. Low Bargaining Power of Suppliers
3.3.3. Moderate Threat of Substitutes
3.3.4. Low Threat of New Entrants
3.3.5. Moderate Competitive Rivalry

3.4. Top Player Positioning
3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. Surge In Autoimmune Disorders
3.5.1.2. Increase In Demand For Organ Transplantation

3.5.2. Restraint

3.5.2.1. Lack of Awareness Towards Organ Transplantation

3.5.3. Opportunity

3.5.3.1. Various Growth Opportunities In Emerging Economies

Chapter 4: Immunosuppressant Market, By Indication

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Organ Transplantation

4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Share Analysis, By Country

4.3. Autoimmune Disorders

4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Share Analysis, By Country

4.4. Other Diseases

4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Share Analysis, By Country

Chapter 5: Immunosuppressant Market, By Drug Class

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Calcineurin Inhibitors

5.2.1. Market Size And Forecast
5.2.2. Market Share Analysis, By Country

5.3. Corticosteroids

5.3.1. Market Size And Forecast
5.3.2. Market Share Analysis, By Country

5.4. Monoclonal Antibodies (Mabs)

5.4.1. Market Size And Forecast
5.4.2. Market Share Analysis, By Country

5.5. Mtor Inhibitors

5.5.1. Market Size And Forecast
5.5.2. Market Share Analysis, By Country

5.6. Other Immunosuppressants

5.6.1. Market Size And Forecast
5.6.2. Market Share Analysis, By Country

Chapter 6: Immunosuppressants Market, By Distribution Channel

6.1. Overview

6.1.1. Market Size And Forecast

6.2. Hospital Pharmacies

6.2.1. Market Size And Forecast
6.2.2. Market Share Analysis, By Country

6.3. Retail Pharmacies

6.3.1. Market Size And Forecast
6.3.2. Market Share Analysis, By Country

6.4. Online Pharmacy

6.4.1. Market Size And Forecast
6.4.2. Market Share Analysis, By Country

Chapter 7: Immunosuppressant Market, By Region

7.1. Overview

7.1.1. Market Size And Forecast

7.2. North America

7.2.1. Key Market Trends And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.3. Market Size And Forecast, By Indication
7.2.4. Market Size And Forecast, By Drug Class
7.2.5. Market Size And Forecast, By Distribution Channel
7.2.6. U.S.

7.2.6.1. U.S. Market Size And Forecast, By Indication
7.2.6.2. U.S. Market Size And Forecast, By Drug Class
7.2.6.3. U.S. Market Size And Forecast, By Distribution Channel

7.2.7. Canada

7.2.7.1. Canada Market Size And Forecast, By Indication
7.2.7.2. Canada Market Size And Forecast, By Drug Class
7.2.7.3. Canada Market Size And Forecast, By Distribution Channel

7.2.8. Mexico

7.2.8.1. Mexico Market Size And Forecast, By Indication
7.2.8.2. Mexico Market Size And Forecast, By Drug Class
7.2.8.3. Mexico Market Size And Forecast, By Distribution Channel

7.3. Europe

7.3.1. Key Growth Factors And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.3. Market Size And Forecast, By Indication
7.3.4. Market Size And Forecast, By Drug Class
7.3.5. Market Size And Forecast, By Distribution Channel
7.3.6. Germany

7.3.6.1. Germany Market Size And Forecast, By Indication
7.3.6.2. Germany Market Size And Forecast, By Drug Class
7.3.6.3. Germany Market Size And Forecast, By Distribution Channel

7.3.7. France

7.3.7.1. France Market Size And Forecast, By Indication
7.3.7.2. France Market Size And Forecast, By Drug Class
7.3.7.3. France Market Size And Forecast, By Distribution Channel

7.3.8. Uk

7.3.8.1. Uk Market Size And Forecast, By Indication
7.3.8.2. Uk Market Size And Forecast, By Drug Class
7.3.8.3. Uk Market Size And Forecast, By Distribution Channel

7.3.9. Italy

7.3.9.1. Italy Market Size And Forecast, By Indication
7.3.9.2. Italy Market Size And Forecast, By Drug Class
7.3.9.3. Italy Market Size And Forecast, By Distribution Channel

7.3.10. Rest of Europe

7.3.10.1. Rest of Europe Market Size And Forecast, By Indication
7.3.10.2. Rest of Europe Market Size And Forecast, By Drug Class
7.3.10.3. Rest of Europe Market Size And Forecast, By Distribution Channel

7.4. Asia-Pacific

7.4.1. Key Growth Factors And Opportunities.
7.4.2. Market Size And Forecast, By Country
7.4.3. Market Size And Forecast, By Indication
7.4.4. Market Size And Forecast, By Drug Class
7.4.5. Market Size And Forecast, By Distribution Channel
7.4.6. Japan

7.4.6.1. Japan Market Size And Forecast, By Indication
7.4.6.2. Japan Market Size And Forecast, By Drug Class
7.4.6.3. Japan Market Size And Forecast, By Distribution Channel

7.4.7. China

7.4.7.1. China Market Size And Forecast, By Indication
7.4.7.2. China Market Size And Forecast, By Drug Class
7.4.7.3. China Market Size And Forecast, By Distribution Channel

7.4.8. India

7.4.8.1. India Market Size And Forecast, By Indication
7.4.8.2. India Market Size And Forecast, By Drug Class
7.4.8.3. India Market Size And Forecast, By Distribution Channel

7.4.9. Australia

7.4.9.1. Australia Market Size And Forecast By Indication
7.4.9.2. Australia Market Size And Forecast, By Drug Class
7.4.9.3. Australia Market Size And Forecast, By Distribution Channel

7.4.10. Rest of Asia-Pacific

7.4.10.1. Rest of Asia-Pacific Market Size And Forecast By Indication
7.4.10.2. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
7.4.10.3. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel

7.5. Lamea

7.5.1. Key Growth Factors And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.3. Market Size And Forecast, By Indication
7.5.4. Market Size And Forecast, By Drug Class
7.5.5. Market Size And Forecast, By Distribution Channel
7.5.6. Brazil

7.5.6.1. Brazil Market Size And Forecast, By Indication
7.5.6.2. Brazil Market Size And Forecast, By Drug Class
7.5.6.3. Brazil Market Size And Forecast, By Distribution Channel

7.5.7. Saudi Arabia

7.5.7.1. Saudi Arabia Market Size And Forecast, By Indication
7.5.7.2. Saudi Arabia Market Size And Forecast, By Drug Class
7.5.7.3. Saudi Arabia Market Size And Forecast, By Distribution Channel

7.5.8. South Africa

7.5.8.1. South Africa Market Size And Forecast, By Indication
7.5.8.2. South Africa Market Size And Forecast, By Drug Class
7.5.8.3. South Africa Market Size And Forecast, By Distribution Channel

7.5.9. Rest of Lamea

7.5.9.1. Rest of Lamea Market Size And Forecast, By Indication
7.5.9.2. Rest of Lamea Market Size And Forecast, By Drug Class
7.5.9.3. Rest of Lamea Market Size And Forecast, By Distribution Channel

Chapter 8: Company Profiles

8.1. Abbvie Inc.

8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments

8.2. Astellas Pharma Inc.

8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance

8.3. Bristol-Myers Squibb Company

8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves And Developments

8.4. Glaxosmithkline Plc.

8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves And Developments

8.5. Intas Pharmaceuticals Ltd. (Accord Healthcare Ltd.)

8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance

8.6. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments

8.7. Mylan N.V.

8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves And Developments

8.8. Novartis International Ag (Sandoz)

8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments

8.9. Pfizer Inc.

8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.9.6. Key Strategic Moves And Developments

8.10. Sanofi S.A.

8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments

List of Tables

Table 01. Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 02. Immunosuppresants Market For Organ Transplantation Market, By Region, 2018-2026 ($Million)
Table 03. Immunosuppressant Market For Autoimmune Disorders, By Region, 2018-2026 ($Million)
Table 04. Immunosuppressants Market For Others, By Region, 2018-2026 ($Million)
Table 05. Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 06. Calcineurin Inhibitors Immunosuppressant Market, By Region, 2018-2026 ($Million)
Table 07. Immunosuppressant Corticosteroidss Market, By Region, 2018-2026 ($Million)
Table 08. Monoclonal Antibodies Immunosuppressant Market, By Region, 2018-2026 ($Million)
Table 09. Mtor Inhibitors Immunosuppressant Market, By Region, 2018-2026 ($Million)
Table 10. Other Immunosuppressant Market, By Region, 2018-2026 ($Million)
Table 11. Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 12. Immunosuppressant Market For Hospital Pharmacies, By Region, 2018-2026 ($Million)
Table 13. Immunosuppressant Corticosteroidss Market For Retail Pharmacies, By Region, 2018-2026 ($Million)
Table 14. Immunosuppressant Market For Online Pharmacy, By Region, 2018-2026 ($Million)
Table 15. Immunosuppressant Market, By Region, 2018-2026 ($Million)
Table 16. North America Immunosuppressant Market, By Country, 2018-2026 ($Million)
Table 17. North America Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 18. North America Immunosuppressant Market, By Drug Class, 2018–2026 ($Million)
Table 19. North America Immunosuppressant Market, By Distribution Cahnnel, 2018-2026 ($Million)
Table 20. U.S. Immunosuppressant Market By Indication, 2018-2026 ($Million)
Table 21. U.S. Immunosuppressant Market By Drug Class, 2018-2026 ($Million)
Table 22. U.S. Immunosuppressant Market By Distribution Channel, 2018-2026 ($Million)
Table 23. Canada Immunosuppressant Market By Indication, 2018-2026 ($Million)
Table 24. Canada Immunosuppressant Market By Drug Class, 2018-2026 ($Million)
Table 25. Canada Immunosuppressant Market By Distribution Channel, 2018-2026 ($Million)
Table 26. Mexico Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 27. Mexico Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 28. Mexico Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 29. Europe Immunosuppressant Market, By Country, 2018-2026 ($Million)
Table 30. Europe Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 31. Europe Immunosuppressant Market, By Drug Class, 2018–2026 ($Million),
Table 32. Europe Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 33. Germany Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 34. Germany Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 35. Germany Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 36. France Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 37. France Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 38. France Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 39. U.K. Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 40. U.K. Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 41. U.K. Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 42. Italy Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 43. Italy Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 44. Italy Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 45. Rest of Europe Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 46. Rest of Europe Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 47. Rest of Europe Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 48. Asia-Pacific Immunosuppressant Market, By Country, 2018-2026 ($Million)
Table 49. Asia-Pacific Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 50. Asia-Pacific Immunosuppressant Market, By Drug Class, 2018–2026 ($Million),
Table 51. Asia-Pacific Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 52. Japan Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 53. Japan Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 54. Japan Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 55. China Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 56. China Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 57. China Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 58. India Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 59. India Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 60. India Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 61. Australia Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 62. Australia Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 63. Australia Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 64. Rest of Asia-Pacific Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 65. Rest of Asia-Pacific Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 66. Rest of Asia-Pacific Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 67. Lamea Immunosuppressant Market, By Country, 2018-2026 ($Million)
Table 68. Lamea Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 69. Lamea Immunosuppressant Market, By Drug Class, 2018–2026 ($Million),
Table 70. Lamea Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 71. Brazil Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 72. Brazil Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 73. Brazil Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 74. Saudi Arabia Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 75. Saudi Arabia Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 76. Saudi Arabia Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 77. South Africa Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 78. South Africa Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 79. South Africa Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 80. Rest of Lamea Immunosuppressant Market, By Indication, 2018-2026 ($Million)
Table 81. Rest of Lamea Immunosuppressant Market, By Drug Class, 2018-2026 ($Million)
Table 82. Rest of Lamea Immunosuppressant Market, By Distribution Channel, 2018-2026 ($Million)
Table 83. Abbvie: Company Snapshot
Table 84. Abbvie: Operating Segments
Table 85. Abbott: Product Portfolio
Table 86. Astellas: Company Snapshot
Table 87. Astellas: Products And Services
Table 88. Astellas: Product Portfolio
Table 89. Bms: Company Snapshot
Table 90. Bms: Product Portfolio
Table 91. Gsk: Company Snapshot
Table 92. Gsk: Operating Segments
Table 93. Gsk: Product Portfolio
Table 94. Intas: Company Snapshot
Table 95. Intas: Product Portfolio
Table 96. J&J: Company Snapshot
Table 97. J&J: Operating Segments
Table 98. J&J: Product Portfolio
Table 99. Mylan: Company Snapshot
Table 100. Mylan: Operating Segments
Table 101. Mylan: Product Portfolio
Table 102. Novartis Ag: Company Snapshot
Table 103. Novartis: Operating Segments
Table 104. Novartis Ag: Product Portfolio
Table 105. Pfizer: Company Snapshot
Table 106. Pfizer: Operating Segments
Table 107. Pfizer: Product Portfolio
Table 108. Sanofi: Company Snapshot
Table 109. Sanofi: Operating Segments
Table 110. Sanofi: Product Portfolio

List of Figures

Figure 01. Immunosuppressant, Market Segmentation
Figure 02. Top Investment Pockets
Figure 03. Top Player Positioning
Figure 04. Drivers, Restraint, And Opportunity, Immunosuppressants Market
Figure 05. Comparative Share Analysis of Immunosuppresants Market For Organ Transplantation, By Country, 2018 & 2026 (%)
Figure 06. Comparative Share Analysis of Immunosuppressant Market For Autoimmune Disorders Market, By Country, 2018 & 2026 (%)
Figure 07. Comparative Share Analysis of Immunosuppressants Market For Others, By Country, 2018 & 2026 (%)
Figure 08. Comparative Share Analysis of Calcineurin Inhibitors Market, By Country, 2018 & 2026 (%)
Figure 09. Comparative Share Analysis of Corticosteroidss Immunosuppressant Market, By Country, 2018 & 2026 (%)
Figure 10. Comparative Share Analysis of Monoclonal Antibodies Immunosuppressant Market, By Country, 2018 & 2026 (%)
Figure 11. Comparative Share Analysis of Mtor Inhibitors Immunosuppressant Market, By Country, 2018 & 2026 (%)
Figure 12. Comparative Share Analysis of Other Immunosuppressant Market, By Country, 2018 & 2026 (%)
Figure 13. Comparative Share Analysis of Immunosuppressant Market For Hospital Pharmacies, By Country, 2018 & 2026 (%)
Figure 14. Comparative Share Analysis of Retail Pharmacies Market, By Country, 2018 & 2026 (%)
Figure 15. Comparative Share Analysis of Online Pharmecy Market, By Country, 2018 & 2026 (%)
Figure 16. Abbvie: Net Sales, 2016–2018 ($Million)
Figure 17. Abbvie: Revenue Share By Segment, 2018 (%)
Figure 18. Abbvie: Revenue Share By Region, 2018 (%)
Figure 19. Astellas: Sales, 2016–2018 ($Million)
Figure 20. Astellas: Sales Share By Products And Services, 2018 (%)
Figure 21. Astellas: Revenue Share By Region, 2018 (%)
Figure 22. Bms: Net Sales, 2016–2018 ($Million)
Figure 23. Bms: Revenue Share By Region, 2018 (%)
Figure 24. Gsk: Revenue, 2016–2018 ($Million)
Figure 25. Gsk: Revenue Share By Segment, 2018 (%)
Figure 26. Gsk: Revenue Share By Region, 2018 (%)
Figure 27. Intas: Revenue, 2016–2018 ($Million)
Figure 28. Intas: Revenue Share By Region, 2018 (%)
Figure 29. J&J: Revenue, 2016–2018 ($Million)
Figure 30. J&J: Revenue Share By Segment, 2018 (%)
Figure 31. J&J: Revenue Share By Region, 2018 (%)
Figure 32. Mylan: Net Sales, 2016–2018 ($Million)
Figure 33. Mylan: Revenue Share By Geography, 2018 (%)
Figure 34. Novartis: Net Sales, 2016–2018 ($Million)
Figure 35. Novartis: Revenue Share By Segment, 2018 (%)
Figure 36. Novartis: Revenue Share By Geography, 2018 (%)
Figure 37. Pfizer: Revenue, 2016–2018 ($Million)
Figure 38. Pfizer: Revenue Share By Segment, 2018 (%)
Figure 39. Pfizer: Revenue Share By Region, 2018 (%)
Figure 40. Sanofi: Net Sales, 2016–2018 ($Million)
Figure 41. Sanofi: Revenue Share By Segment, 2018 (%)
Figure 42. Sanofi: Revenue Share By Region, 2018 (%)



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 免疫抑制剤の世界市場2019-2026:機会分析・産業予測(Immunosuppressants Market by Drug class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, and Others), Indication (Organ Transplantation, Autoimmune Disorders, and Non-Autoimmune Inflammatory Diseases), and Distribution channel (Hospital pharmacies, Retail pharmacies and Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2019–2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆